Objective
The consortium seeks to develop a highly novel bone substitute material (BSM) from mineralized silk composites for use in medical procedures requiring bone tissue replacement. Spinox have developed Spidrex, a novel silk-silk composite based on a fibre and matrix generated from spider silk analogues. Spidrex is biocompatible, bio-absorbable and has excellent mechanical properties and cell adhesiveness. Pilot studies at Bristol have shown it is rapidly and heavily mineralised by the component of natural bone, hydroxyapatite. Mineralised Spidrex will be developed into a BSM by incorporating osteoinductive factors in the silk matrix and biochemical tailoring both fibre and matrix. Progentix will develop non-foetal stem cell technology with which to seed the BSM. 3H Biomedical and U Kon InPuT will test human cell reaction to BSM in vitro. This will reduce the need for animal trials and allow material modification early in the design process.
Soton will optimise bone formation in the BSM in vitro. A cellularised, load bearing, resorbable BSM is unprecedented and will provide entry to a market estimated at 2.5 billion euros. It will be particularly advantageous for the treatment of fractures resulting from osteoporosis and bone lesions in cancer patients. The consortium comprises 3 highly innovative, research based SMEs from 3 member states whose competitiveness will be enhanced by access to this market and by collaboration with the consortium's 5 leading RTDs. Individually, each SME does not have the capability to pursue a project of the above magnitude. Tissue engineering, adult stem cell research and implantable biomaterials have been flagged as future growth markets, keenly pursued in the U.S. and Asia. Developing know-how in these areas, and subsequent dissemination of results in Europe will increase E.U. competitiveness in these burgeoning sectors.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences medical biotechnology tissue engineering
- medical and health sciences medical biotechnology cells technologies stem cells
- medical and health sciences clinical medicine oncology
- engineering and technology industrial biotechnology biomaterials
- medical and health sciences medical biotechnology implants artificial bone
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2003-SME-1
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
NEWBURY
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.